Evidence map›Paper›PMID 19475619›Full record

ArticleJournal of medical virology2009

Investigation of pre-diagnostic virological markers for progressive multifocal leukoencephalopathy in human immunodeficiency virus-infected patients.

Mary K Grabowski, Raphael P Viscidi, Joseph B Margolick, Lisa P Jacobson, Keerti V Shah

Abstract read
In one paragraph

Article in Journal of medical virology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Multiplex qPCR assay for ultra sensitive detection of JCV DNA with simultaneous identification of genotypes that discriminates non-virulent from virulent variants.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2013
    Article
  4. JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2011
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Mary K GrabowskiJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA. mgrabows@jhsph.edu
Raphael P Viscidi
Joseph B Margolick
Lisa P Jacobson
Keerti V Shah
Johns Hopkins University · US

Funding

NATURAL HISTORY OF AIDS IN HOMOSEXUAL MENU01AI035040 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DETELS, ROGER, MARTINEZ-MAZA, OTONIEL · 1993 to 2018
$75.2M
University of Pittsburgh Multicenter AIDS Cohort Study (MACS)U01AI035041 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MARTINSON, JEREMY JAMES, RINALDO, CHARLES R · 1993 to 2018
$71.4M
MULTICENTER AIDS COHORT STUDYU01AI035039 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WOLINSKY, STEVEN M · 1993 to 2018
$66.4M
Multicenter Aids Cohort Study- Part B (Baltimore Site)U01AI035042 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BROWN, TODD T, MARGOLICK, JOSEPH B. · 1993 to 2018
$61.5M
METHODOLOGICAL EXPERTISE IN INTREPRETING MACS DATAU01AI035043 · NIAID · JOHNS HOPKINS UNIVERSITY · PI JACOBSON, LISA P · 1993 to 2011
$26.9M
MULTICENTER AIDS COHORT STUDY PATHOGENESIS RESEARCH LABSU01AI037613 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JAMIESON-KARAVODIN, BETH DEIRDRE · 1995 to 2003
$3.4M
MULTICENTER AIDS COHORT STUDY PATHOGENESIS RESEARCHU01AI037984 · NIAID · JOHNS HOPKINS UNIVERSITY · PI MARGOLICK, JOSEPH B. · 1995 to 2003
$3.1M
Immune Response to Polyomavirus InfectionR01AI063360 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI RANDHAWA, PARMJEET S · 2006 to 2010
$2.0M
Nested case-control study of JC virus infection and incident colorectal cancerR01CA118348 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI ROLLISON, DANA ELISE · 2006 to 2008
$905k
ZIDOVUDINE WITH PROBENECID--EFFECTS OF PROBENECID ON ZIDOVUDINEM01RR000722 · NCRR · JOHNS HOPKINS UNIVERSITY · 1985 to 1996
–
NCI NIH HHS CA118348NCI NIH HHS R01 CA118348NCRR NIH HHS 5-MO1-RR-00722NCRR NIH HHS M01 RR000722NIAID NIH HHS R01 AI063360NIAID NIH HHS R01 AI63360NIAID NIH HHS U01 AI035039NIAID NIH HHS U01 AI035040NIAID NIH HHS U01 AI035041NIAID NIH HHS U01 AI035042NIAID NIH HHS U01 AI035043NIAID NIH HHS U01 AI037613NIAID NIH HHS U01 AI037984NIAID NIH HHS UO1-AI-35039NIAID NIH HHS UO1-AI-35040NIAID NIH HHS UO1-AI-35041NIAID NIH HHS UO1-AI-35042NIAID NIH HHS UO1-AI-35043NIAID NIH HHS UO1-AI-37613NIAID NIH HHS UO1-AI-37984
6 · The paper itself

Abstract

Progressive multifocal leukoencephalopathy (PML) is a severe neurological disorder due to JC virus (JCV) infection. Pre-diagnostic biological markers and risk factors for PML are not well understood. We conducted a case-control study nested within the Multicenter AIDS Cohort Study to examine the association between JCV viruria and viremia and serum antibody to JCV capsids, in relation to subsequent PML diagnoses, 5 months to 12 years later. Other demographic and immunologic factors were also examined. The study population included 28 incident cases of PML, 26 matched HIV-positive controls, and 50 HIV-negative controls. Prevalence of JCV viruria was 37% in cases, 42% in HIV-positive controls, and 28% in HIV-negative controls (P = 0.43). Among persons with JCV viruria, persistent viruria was more common in cases (89%) than in HIV-positive controls (33%) (P = 0.02). Presence of JCV viruria was not related to the time to PML diagnosis (OR: 1.03, 95% CI: 0.8-1.4); however, the urinary concentration of JCV DNA increased with proximity to the date of PML diagnosis in cases. JCV seropositivity did not differ between cases or controls (P = 0.42). Four cases tested JCV seronegative, including one case only 5 months prior to diagnosis with PML. JCV DNA was detected in the serum of one HIV-positive control. Smoking was the only demographic variable analyzed associated with an increased risk for PML (MOR: 9.0, 95% CI: 1.2-394.5). The results suggest that persistent JCV viruria and increasing urinary concentration of JCV DNA may be predictive of PML for some patients.

Indexed as

AdultAgedAntibodies, ViralBiomarkersBloodCase-Control StudiesDNA, ViralHIV InfectionsHumansJC VirusLeukoencephalopathy, Progressive MultifocalMaleMiddle AgedRisk FactorsUrineYoung AdultAntibodies, ViralBiomarkersDNA, Viral

Identifiers

PMID19475619
PMCPMC2969173
OpenAlexW2024751870

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.